PE20190394A1 - ANTI-C5 ANTIBODIES AND METHODS OF USE - Google Patents
ANTI-C5 ANTIBODIES AND METHODS OF USEInfo
- Publication number
- PE20190394A1 PE20190394A1 PE2018003148A PE2018003148A PE20190394A1 PE 20190394 A1 PE20190394 A1 PE 20190394A1 PE 2018003148 A PE2018003148 A PE 2018003148A PE 2018003148 A PE2018003148 A PE 2018003148A PE 20190394 A1 PE20190394 A1 PE 20190394A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- antibody
- binds
- affinity
- substitution
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 238000006467 substitution reaction Methods 0.000 abstract 2
- 102220471255 Guanine nucleotide exchange factor subunit RIC1_E48A_mutation Human genes 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Referido a un anticuerpo que se une a C5, anti-C5, caracterizado porque se une a un epitopo dentro de la cadena beta de C5 con una afinidad mas alta a pH neutro que a pH acido. Este anticuerpo se caracteriza por que entra en contacto con los aminoacidos D51 y K109 de C5 (SEC ID NO:39); la afinidad del anticuerpo por C5 (SEC ID NO:39) es mayor que la afinidad del anticuerpo por un mutante C5 que consiste en una sustitucion E48A de la SEC ID NO: 39; y se une a una proteina C5 que consiste en la secuencia de aminoacidos de la SEC ID NO: 40 a pH 7.4, pero no se une a una proteina C5 que consiste en la secuencia de aminoacidos de la SEC ID NO: 39 con una sustitucion de H72Y a pH 7.4. Tambien se refiere a un metodo para producir el citado anticuerpo.Refers to an antibody that binds to C5, anti-C5, characterized in that it binds to an epitope within the beta chain of C5 with a higher affinity at neutral pH than at acidic pH. This antibody is characterized in that it comes into contact with amino acids D51 and K109 of C5 (SEQ ID NO: 39); the affinity of the antibody for C5 (SEQ ID NO: 39) is greater than the affinity of the antibody for a C5 mutant consisting of an E48A substitution of SEQ ID NO: 39; and binds to a C5 protein consisting of the amino acid sequence of SEQ ID NO: 40 at pH 7.4, but does not bind to a C5 protein consisting of the amino acid sequence of SEQ ID NO: 39 with a substitution of H72Y at pH 7.4. It also refers to a method of producing said antibody.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016120325 | 2016-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190394A1 true PE20190394A1 (en) | 2019-03-13 |
Family
ID=59969459
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002969A PE20240825A1 (en) | 2016-06-17 | 2017-06-16 | ANTI-C5 ANTIBODIES AND METHODS OF USE |
| PE2018003148A PE20190394A1 (en) | 2016-06-17 | 2017-06-16 | ANTI-C5 ANTIBODIES AND METHODS OF USE |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002969A PE20240825A1 (en) | 2016-06-17 | 2017-06-16 | ANTI-C5 ANTIBODIES AND METHODS OF USE |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3472316A4 (en) |
| JP (3) | JP6202774B1 (en) |
| KR (2) | KR101852739B1 (en) |
| CN (3) | CN109312326B (en) |
| AU (1) | AU2017285763B2 (en) |
| BR (1) | BR112018075688A2 (en) |
| CA (1) | CA3021956A1 (en) |
| CL (1) | CL2018003573A1 (en) |
| CR (1) | CR20190013A (en) |
| EA (1) | EA201990018A1 (en) |
| IL (2) | IL300611A (en) |
| MX (2) | MX2018015030A (en) |
| MY (1) | MY187848A (en) |
| PE (2) | PE20240825A1 (en) |
| PH (1) | PH12018502354A1 (en) |
| SG (2) | SG10201800265UA (en) |
| TW (4) | TWI789369B (en) |
| UA (1) | UA126561C2 (en) |
| WO (1) | WO2017217524A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4342995A3 (en) | 2006-03-31 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| EP3056513A1 (en) | 2008-04-11 | 2016-08-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| RU2658504C9 (en) | 2010-11-30 | 2018-08-21 | Чугаи Сейяку Кабусики Кайся | Antigen-binding molecule, that is capable of multiple binding with a lot of antigenic molecules |
| TW201809008A (en) | 2014-12-19 | 2018-03-16 | 日商中外製藥股份有限公司 | Anti-C5 antibodies and methods of use |
| KR102534895B1 (en) | 2016-06-14 | 2023-05-24 | 리제너론 파아마슈티컬스, 인크. | Anti-C5 Antibodies and Uses Thereof |
| CN109312326B (en) * | 2016-06-17 | 2022-09-09 | 中外制药株式会社 | anti-C5 antibodies and methods of use |
| TW202300168A (en) | 2016-08-05 | 2023-01-01 | 日商中外製藥股份有限公司 | Composition for prophylaxis or treatment of il-8 related diseases |
| EP3692064A1 (en) * | 2017-10-04 | 2020-08-12 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis |
| AU2018383751A1 (en) | 2017-12-13 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibody combinations and uses thereof |
| JP2021536509A (en) * | 2018-09-06 | 2021-12-27 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Humanized anti-C5 antibody and its use |
| AU2020261073A1 (en) * | 2019-04-24 | 2021-12-16 | Kira Pharmaceuticals (Us) Llc | Bi-functional humanized anti-C5 antibodies and factor H fusion proteins and uses thereof |
| CN113563467A (en) * | 2020-04-28 | 2021-10-29 | 上海普铭生物科技有限公司 | Antibodies against human complement protein C5 and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0230985Y2 (en) | 1985-07-08 | 1990-08-21 | ||
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| JP4643139B2 (en) | 2001-06-12 | 2011-03-02 | テレフオンアクチーボラゲット エル エム エリクソン（パブル） | Synchronization in the UMTS Terrestrial Radio Access Network (UTRAN) |
| US7432356B2 (en) | 2001-08-17 | 2008-10-07 | Genentech, Inc. | Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b |
| JP4333939B2 (en) | 2001-08-27 | 2009-09-16 | ロード・コーポレーション | Trolley wire suspension system |
| DE10253331A1 (en) | 2002-11-14 | 2004-06-03 | Symrise Gmbh & Co. Kg | Use of trans-pellitori as a flavoring |
| US7267849B2 (en) | 2004-03-02 | 2007-09-11 | Nitto Denko Corporation | Compensator for liquid crystal display |
| KR20080069889A (en) | 2007-03-20 | 2008-07-29 | (주)화도 | Pe pipe |
| WO2008113834A2 (en) * | 2007-03-22 | 2008-09-25 | Novartis Ag | C5 antigens and uses thereof |
| US8420298B2 (en) | 2007-04-11 | 2013-04-16 | Sekisui Chemical Co., Ltd. | Method for production of crosslinked polyvinyl acetal resin, and crosslinked polyvinyl acetal resin |
| EP3056513A1 (en) * | 2008-04-11 | 2016-08-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| EP2328616B1 (en) * | 2008-08-05 | 2015-04-29 | Novartis AG | Compositions and methods for antibodies against complement protein c5 |
| KR20100054403A (en) | 2008-11-14 | 2010-05-25 | 삼성전자주식회사 | Online composition apparatus and method for writing by multiple participants |
| TW201206466A (en) * | 2010-03-11 | 2012-02-16 | Rinat Neuroscience Corp | Antibodies with pH dependent antigen binding |
| BR112012022917A2 (en) * | 2010-03-11 | 2017-01-10 | Pfizer | ph-dependent antigen binding antibodies |
| KR20110111007A (en) | 2010-04-02 | 2011-10-10 | 이화여자대학교 산학협력단 | Octahydro-binaphthol derivatives for l/d optical conversion and optical resolution |
| KR20110122011A (en) | 2010-05-03 | 2011-11-09 | 황보철종 | System for administrating combine store point and method therefor |
| WO2014028354A1 (en) * | 2012-08-13 | 2014-02-20 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
| US10280215B2 (en) * | 2013-01-31 | 2019-05-07 | Seoul National University R&Db Foundation | Anti-C5 antibodies and methods of treating complement-related diseases |
| EP2978451B1 (en) * | 2013-03-29 | 2019-11-27 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| TW201809008A (en) * | 2014-12-19 | 2018-03-16 | 日商中外製藥股份有限公司 | Anti-C5 antibodies and methods of use |
| CA3005592C (en) * | 2015-12-18 | 2024-01-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
| CN109312326B (en) * | 2016-06-17 | 2022-09-09 | 中外制药株式会社 | anti-C5 antibodies and methods of use |
-
2017
- 2017-06-16 CN CN201780036916.4A patent/CN109312326B/en active Active
- 2017-06-16 CN CN202211018018.5A patent/CN115960223A/en active Pending
- 2017-06-16 CA CA3021956A patent/CA3021956A1/en active Pending
- 2017-06-16 UA UAA201810992A patent/UA126561C2/en unknown
- 2017-06-16 SG SG10201800265UA patent/SG10201800265UA/en unknown
- 2017-06-16 KR KR1020177020545A patent/KR101852739B1/en active IP Right Grant
- 2017-06-16 TW TW106141573A patent/TWI789369B/en active
- 2017-06-16 KR KR1020187010179A patent/KR102226975B1/en active IP Right Grant
- 2017-06-16 JP JP2017118226A patent/JP6202774B1/en active Active
- 2017-06-16 TW TW106120143A patent/TWI610941B/en active
- 2017-06-16 MY MYPI2018002581A patent/MY187848A/en unknown
- 2017-06-16 TW TW112120479A patent/TW202337903A/en unknown
- 2017-06-16 AU AU2017285763A patent/AU2017285763B2/en active Active
- 2017-06-16 CN CN202211023851.9A patent/CN115925922A/en active Pending
- 2017-06-16 SG SG11201705584VA patent/SG11201705584VA/en unknown
- 2017-06-16 CR CR20190013A patent/CR20190013A/en unknown
- 2017-06-16 EP EP17813418.5A patent/EP3472316A4/en active Pending
- 2017-06-16 BR BR112018075688-1A patent/BR112018075688A2/en unknown
- 2017-06-16 PE PE2023002969A patent/PE20240825A1/en unknown
- 2017-06-16 WO PCT/JP2017/022253 patent/WO2017217524A1/en active Application Filing
- 2017-06-16 MX MX2018015030A patent/MX2018015030A/en unknown
- 2017-06-16 PE PE2018003148A patent/PE20190394A1/en unknown
- 2017-06-16 IL IL300611A patent/IL300611A/en unknown
- 2017-06-16 TW TW111107923A patent/TWI807666B/en active
- 2017-06-16 EA EA201990018A patent/EA201990018A1/en unknown
- 2017-08-28 JP JP2017162934A patent/JP7032077B2/en active Active
-
2018
- 2018-11-08 PH PH12018502354A patent/PH12018502354A1/en unknown
- 2018-12-04 MX MX2023001360A patent/MX2023001360A/en unknown
- 2018-12-12 IL IL263657A patent/IL263657A/en unknown
- 2018-12-12 CL CL2018003573A patent/CL2018003573A1/en unknown
-
2022
- 2022-02-24 JP JP2022026406A patent/JP2022091748A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190394A1 (en) | ANTI-C5 ANTIBODIES AND METHODS OF USE | |
| CL2020001974A1 (en) | Anti-trem2 antibodies and methods of using them. (divisional request 201903093) | |
| CL2019000668A1 (en) | Antibodies against alpha regulatory signal protein and use procedures. | |
| PE20171111A1 (en) | ANTIMIOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT HR REGIONS, AND METHODS OF USE | |
| SA518391704B1 (en) | Anti-C5 Antibodies and Methods of Use | |
| PH12017501114A1 (en) | Anti-c5 antibodies and methods of use | |
| AR122964A2 (en) | PEPTIDES USEFUL IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER TYPES OF CANCER | |
| CL2019003657A1 (en) | Antibodies that specifically bind to cd38 useful for enhancing an immune response in a patient. (divisional request 201703275) | |
| PE20200757A1 (en) | AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND ITS USES | |
| UY37928A (en) | ANTI-CD38 ANTIBODIES AND METHODS OF USE | |
| GT201700162A (en) | ANTI-CD3 ANTIBODIES, ANTI-CD123 ANTIBODIES AND BIESPECIFIC ANTIBODIES THAT SPECIFICALLY JOIN CD3 AND / OR CD123 | |
| AR101846A1 (en) | ANTI-CLL-1 ANTIBODIES AND IMMUNOCATE PLAYERS | |
| CU24537B1 (en) | MONOCLONAL ANTIBODIES COMPETING TO JOIN HUMAN TAU WITH THE 3D6 ANTIBODY | |
| BR112013027829A2 (en) | anti-cd40 antibodies and method of use | |
| AR080914A1 (en) | BETA-AMILOID UNION PROTEINS | |
| CU20180135A7 (en) | ISOLATED MONOCLONAL ANTIBODIES COMPETING FOR TAU UNION WITH ANTIBODY 3D6 | |
| ES2639026T3 (en) | Totally human antibodies specific for CADM1 | |
| ES2722773T3 (en) | Modified Meningococcal fHbp Polypeptides | |
| MY193350A (en) | Anti-vegf protein compositions and methods for producing the same | |
| PE20191743A1 (en) | BI-SPECIFIC ANTIBODIES ANTI-PD-L1-ANTI-TIM3 | |
| EA201690056A8 (en) | ARTIFICIAL PROTEINS CONNECTING THE FACTOR N (fHbp), AND METHODS OF THEIR APPLICATION | |
| CL2020002459A1 (en) | C-terminal antibody variants | |
| MX2022008298A (en) | Antibody for skewing sex ratio and methods of use thereof. | |
| AR100427A1 (en) | PROTEINS OF UNION TO ANTIGEN OF HER1 THAT JOIN THE FORK b OF HER1 | |
| CO2022015049A2 (en) | Autonomous knob domain peptides |